An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: August 23, 2011
Last updated: November 2, 2015
Last verified: November 2015
This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment. Data will be collected from patients receiving once monthly Mircera according to standard of care and local labelling during 12 months of treatment.

Anemia, Kidney Disease, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational. Non-interventional Study to Observe the Safety and Efficacy of MIRCERA in the Treatment of Chronic Renal Anemia in Maintenance ESA Treated Patients on Haemodialysis (STABILE)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 2.5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Long-term maintenance of hemoglobin levels [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 185
Study Start Date: June 2010
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with chronic renal anemia on haemodialysis in maintenance ESA treatment

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Stage IV chronic kidney disease, on haemodialysis
  • Chronic renal anemia, on maintenance ESA treatment
  • Hemoglobin concentration between 10.0 an 12 g/dL
  • Continuous maintenance epoetin therapy with the same dosing interval during the previous month

Exclusion Criteria:

  • Contraindications to ESA treatment (e.g. hypersensitivity, non-controlled hypertension)
  • Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
  • Anemia due to hemolysis, pure red cell aplasia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01422824

Macedonia, The Former Yugoslav Republic of
Delcevo, Macedonia, The Former Yugoslav Republic of, 2320
Prilep, Macedonia, The Former Yugoslav Republic of, 7500
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Stip, Macedonia, The Former Yugoslav Republic of, 2000
Struga, Macedonia, The Former Yugoslav Republic of, 6000
Strumica, Macedonia, The Former Yugoslav Republic of, 2400
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche Identifier: NCT01422824     History of Changes
Other Study ID Numbers: ML25067 
Study First Received: August 23, 2011
Last Updated: November 2, 2015
Health Authority: Macedonia: Ministry of Health

Additional relevant MeSH terms:
Chronic Disease
Kidney Diseases
Renal Insufficiency, Chronic
Disease Attributes
Hematologic Diseases
Pathologic Processes
Renal Insufficiency
Urologic Diseases processed this record on February 09, 2016